Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 11Recruiting 6Terminated 4Active not recruiting 3Unknown 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lymphedema 1Head and Neck Neoplasms 1Gynecological Cancers 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1BRAF V600 Colorectal Cancer 1Anxiety Disorders 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Pharmaceutical Preparations × Clear all
NCT07174947 2026-03-24

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Recruiting
240 enrolled

Anxiety Disorders

NCT06912763 2026-01-26

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

M.D. Anderson Cancer Center

Phase 2 Recruiting
250 enrolled
Head & Neck

Fibrosis, Head and Neck Neoplasms, Lymphedema

NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07150247 2025-09-26

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 2 Recruiting
20 enrolled
Gastrointestinal

BRAF V600 Colorectal Cancer

NCT06207734 2025-05-01

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms

NCT04760327 2024-10-17

GynECT

Institute of Oncology Ljubljana

Phase 2 Recruiting
30 enrolled

Gynecological Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡